Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Oncolys BioPharma Inc. <4588> rises as OBP-301 receives FDA fast track designation in U.S.
Oncolys BioPharma shares surge on regulatory compliance approval for OBP-301
Oncolys BioPharma receives 'conformity' notification for OBP-301 document review and GCP inspection
Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2025 [Japanese GAAP]
Oncolys BioPharma, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 [Japanese GAAP]
Oncolys BioPharma, Jul-Sep (3Q) Net Income Loss Narrows
Oncolys BioPharma, First Half Net Income Loss Widens, Apr-Jun Net Income Loss Widens
Non-consolidated Financial Results for the Six Months Ended June 30, 2025 [Japanese GAAP]
Oncolys BioPharma, Jan-Mar (1Q) Net Income Loss Widens
Non-consolidated Financial Results for the Three Months Ended March 31, 2025 [Japanese GAAP]
Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Japanese GAAP]
Oncolys BioPharma, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
(Delayed) Announcement of Final Safety and Clinical Complete Response Data Presentation of Phase I Clinical Trial for OBP-301-CRT at ASCO GI 2025
Oncolys BioPharma Inc., July-September (3Q) Net Income Loss Widens
Non-consolidated Financial Results for the Nine Months Ended September 30, 2024 [Japanese GAAP]